Catecholamines

Basic Neurochemistry

Volumn , Issue , 2012, Pages 283-299

  Gnegy, Margaret E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882560455     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374947-5.00014-6     Document Type: Chapter

References (58)

1. Ahlquist R.P. A study of the adrenotropic receptors. The American Journal of Physiology 1948, 153(3):586-600.
2. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23(6):2008-2013.
3. Anden N.E., Fuxe K., Hamberger B., Hokfelt T. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiologica Scandinavica 1966, 67(3):306-312.
4. Aoki C., Venkatesan C., Go C.G., Forman R., Kurose H. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cerebral Cortex 1998, 8(3):269-277.
5. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends in Pharmacological Sciences 2007, 28(4):166-172.
6. Berry M.D., Juorio A.V., Li X.M., Boulton A.A. Aromatic L-amino acid decarboxylase: A neglected and misunderstood enzyme. Neurochemical Research 1996, 21(9):1075-1087.
7. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Molecular Pharmacology 2001, 60(6):1181-1188.
8. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., et al. International union of pharmacology nomenclature of adrenoceptors. Pharmacological Reviews 1994, 46(2):121-136.
9. Cavalli A., Lattion A.L., Hummler E., Nenniger M., Pedrazzini T., Aubert J.F., et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(21):11589-11594.
10. Chen L., Zhuang X. Transgenic mouse models of dopamine deficiency. Annals of Neurology 2003, 54(Suppl. 6):S91-102.
11. Chen N., Reith M.E. Substrates dissociate dopamine transporter oligomers. Journal of Neurochemistry 2008, 105(3):910-920.
12. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318(5854):1258-1265.
13. Chruscinski A.J., Rohrer D.K., Schauble E., Desai K.H., Bernstein D., Kobilka B.K. Targeted disruption of the beta2 adrenergic receptor gene. The Journal of Biological Chemistry 1999, 274(24):16694-16700.
14. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192(4238):481-483.
15. Dahlstrom A., Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964, 20(7):398-399.
16. Diliberto E.J., Daniels A.J., Viveros O.H. Multicompartmental secretion of ascorbate and its dual role in dopamine beta-hydroxylation. The American Journal of Clinical Nutrition 1991, 54(Suppl. 6):1163S-1172S.
17. Dunkley P.R., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., Dickson P.W. Tyrosine hydroxylase phosphorylation: Regulation and consequences. Journal of Neurochemistry 2004, 91(5):1025-1043.
18. Edwards R.H. Neurotransmitter release: Variations on a theme. Current Biology 1998, 8(24):R883-885.
19. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacological Reviews 2004, 56(3):331-349.
20. Fleming W.W., McPhillips J.J., Westfall D.P. Postjunctional supersensitivity and subsensitivity of excitable tissues to drugs. Ergebnisse der Physiologie 1973, 68:55-119.
21. Floor E., Leventhal P.S., Wang Y., Meng L., Chen W. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. Journal of Neurochemistry 1995, 64(2):689-699.
22. Fon E.A., Edwards R.H. Molecular mechanisms of neurotransmitter release. Muscle & Nerve 2001, 24(5):581-601.
23. Gainetdinov R.R., Caron M.G. Monoamine transporters: From genes to behavior. Annual Review of Pharmacology and Toxicology 2003, 43:261-284.
24. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Annual Review of Neuroscience 2004, 27:107-144.
25. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(17):9991-9996.
26. Gu H., Wall S.C., Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. The Journal of Biological Chemistry 1994, 269(10):7124-7130.
27. Hein L., Altman J.D., Kobilka B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999, 402(6758):181-184.
28. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(7):4029-4034.
29. Kopin I.J. Catecholamine metabolism: Basic aspects and clinical significance. Pharmacological Reviews 1985, 37(4):333-364.
30. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. Journal of Neurochemistry 1996, 67(2):443-462.
31. L'Hirondel M., Cheramy A., Godeheu G., Artaud F., Saiardi A., Borrelli E., et al. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Research 1998, 792(2):253-262.
32. Lee F.J., Pei L., Moszczynska A., Vukusic B., Fletcher P.J., Liu F. Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. The EMBO Journal 2007, 26(8):2127-2136.
33. Lefkowitz R.J. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends in Pharmacological Sciences 2004, 25(8):413-422.
34. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: Regional, laminar, and ultrastructural localization. The Journal of Comparative Neurology 2001, 432(1):119-136.
35. Makaritsis K.P., Handy D.E., Johns C., Kobilka B., Gavras I., Gavras H. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999, 33(1):14-17.
36. Maley B.E., Engle M.G., Humphreys S., Vascik D.A., Howes K.A., Newton B.W., et al. Monoamine synaptic structure and localization in the central nervous system. Journal of Electron Microscopy Technique 1990, 15(1):20-33.
37. Mitchell H.A., Weinshenker D. Good night and good luck: Norepinephrine in sleep pharmacology. Biochemical Pharmacology 2010, 79(6):801-809.
38. Nakashima A., Hayashi N., Kaneko Y.S., Mori K., Sabban E.L., Nagatsu T., et al. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. Journal of Neural Transmission 2009, 116(11):1355-1362.
39. Neve K.A., Seamans J.K., Trantham-Davidson H. Dopamine receptor signaling. Journal of Receptor and Signal Transduction Research 2004, 24(3):165-205.
40. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450(7168):383-387.
41. Rohrer D.K., Kobilka B.K. Insights from in vivo modification of adrenergic receptor gene expression. Annual Review of Pharmacology and Toxicology 1998, 38:351-373.
42. Rokosh D.G., Simpson P.C. Knockout of the alpha 1A/C-adrenergic receptor subtype: The alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(14):9474-9479.
43. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: From genes to behavior. Annual Review of Neuroscience 1999, 22:197-217.
44. Siow Y.L., Dakshinamurti K. Neuronal dopa decarboxylase. Annals of the New York Academy of Sciences 1990, 585:173-188.
45. Skinbjerg M., Liow J.S., Seneca N., Hong J., Lu S., Thorsell A., et al. D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model. NeuroImage 2010, 50(4):1402-1407.
46. Smiley J.F., Levey A.I., Ciliax B.J., Goldman-Rakic P.S. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: Predominant and extrasynaptic localization in dendritic spines. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(12):5720-5724.
47. Strange P.G. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological Reviews 2001, 53(1):119-133.
48. Swoap S.J., Weinshenker D., Palmiter R.D., Garber G. Dbh(-/-) mice are hypotensive, have altered circadian rhythms, and have abnormal responses to dieting and stress. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2004, 286(1):R108-113.
49. Tanoue A., Nasa Y., Koshimizu T., Shinoura H., Oshikawa S., Kawai T., et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. The Journal of Clinical Investigation 2002, 109(6):765-775.
50. Trendelenburg U. Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines. Pharmacological Reviews 1966, 18(1):629-640.
51. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biological Psychiatry 2006, 60(2):141-151.
52. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiologica Scandinavica. Supplementum 1971, 367:69-93.
53. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000, 408(6809):199-203.
54. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2000, 20(22):8305-8314.
55. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454(7203):486-491.
56. Weinshenker D., Miller N.S., Blizinsky K., Laughlin M.L., Palmiter R.D. Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(21):13873-13877.
57. Willemsen M.A., Verbeek M.M., Kamsteeg E.J., de Rijk-van Andel J.F., Aeby A., Blau N., et al. Tyrosine hydroxylase deficiency: A treatable disorder of brain catecholamine biosynthesis. Brain 2010, 133(Pt 6):1810-1822.
58. --dependent neurotransmitter transporters. Nature 2005, 437(7056):215-223.